Who owns Summit Therapeutics Inc. (SMMT)? Elite investor 13F holders
2 tracked elite investors reported holding Summit Therapeutics Inc as of 2026-06-30, including D.E. Shaw, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | SUMMIT THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 18118611.00 USD | 1243556.000000 | Shares | reduce | Original filing |
| Tudor Investment | SUMMIT THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Gotham Asset Management | SUMMIT THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 229142.00 USD | 15727.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.